MINI-REVIEWS IN MEDICINAL CHEMISTRY, cilt.19, sa.8, ss.688-705, 2019 (SCI-Expanded)
Background: Since deficit of acetylcholine has been evidenced in the Alzheimer's disease (AD) patients, cholinesterase inhibitors are currently the most specified drug category for the remediation of AD.